Home Posts tagged Wegovy

Wegovy

NEWS DESK

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25 mg was associated with significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison. It is important to note that the FDA recently approved orforglipron
NEWS DESK

The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

The European Commission has approved a new 7.2 mg once‑weekly maintenance dose of Wegovy® (semaglutide injection) for adults living with obesity. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific […]
NEWS DESK

More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy® (semaglutide 7.2 mg), bringing it a step closer to offering individuals with obesity in the EU a new Wegovy® option for even greater weight loss. The new dose of Wegovy® has […]
NEWS DESK

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being

PR News Desk
Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy®), at the European Association for the Study of Diabetes (EASD) 2025, Vienna, Austria. The INFORM survey revealed that individuals experienced a substantial drop in food noise after starting Wegovy® treatment, alongside notable improvements in
NEWS DESK

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

PR News Desk
Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy® (semaglutide 2.4 mg) compared with tirzepatide treatment in people with overweight